Quantum-Si incorporated
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $280.0M
- Price
- $1.28
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.06%
- Volume
- 5.2M
About
Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection. This innovative technology is designed to streamline sample preparation and subsequent sequencing processes. The company offers a unique, proprietary single molecule detection system that draws on advancements from the semiconductor industry. This system is specifically applied to the field of proteomics, paving the way for next-generation protein sequencing. Established in 2013, Quantum-Si's headquarters are located in Guilford, Connecticut.
Quick stats
Shares outstanding218.9M
Computed float168.4M
Float / shares76.9%
Cash runway (months)13.4
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001816431
Websitehttps://www.quantum-si.com
AI Summary
AI-generated1/24
standardbullishoperations update
Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro
Quantum-Si presented interim data at World HUPO 2026 showing its next-generation Proteus platform significantly outperforming the commercially available Platinum Pro across scale, accuracy, peptide identification and protein coverage.
In a control peptide study, Proteus delivered 30x more alignments per single chamber with a 4.8-fold lower median false discovery rate (1.36% vs 6.58%), and a full four-chamber run is projected to yield roughly 60x more alignments than Platinum Pro.
In a 24-protein panel, Proteus detected all 24 proteins versus an average of 20.3 on Platinum Pro, with 4.3x more amino acids detected per run.
The system is still unoptimized; commercial launch is expected in Q2 2027, so the results support the roadmap but are not yet revenue-relevant.
Red flags
- data are interim and from a developmental, non-optimized kit — headline metrics may not carry to commercial product
- risk factors reference Nasdaq listing maintenance concerns, leadership transitions, workforce reductions and future financing needs